Hopp til hovedinnhold
Toggle navigation
Live markets
Search
Search
Search
Search
My profile
My Subscriptions
Watchlists
Quote alerts
Create account
Sign in
NB
FR
EN
PT
NL
NB
DE
IT
Hjem
Company Press Releases
Company press releases
Abonner
Filtre
Filtre
Oppdater
Nullstill
Icon After
Dato
Toggle Visibility
Alle
I dag
Denne uken
Denne måneden
Tilpasset datosøk
Fra
Til
Kategori
Toggle Visibility
Alliances and agreements
Annen informasjonspliktig regulatorisk informasjon
Change in Capital
Commercial operations
Commercial results
Corporate life
Dividend
Eks.dato
Endringer i rettighetene til aksjer / verdipapirer
Flagging
General meeting / Board Meeting
Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll
Ikke-informasjonspliktige pressemeldinger
Income
Innsideinformasjon
Joint venture
Journal / appointments
Kapital- og stemmerettsendringer
Legal
Meetings / events
Meldepliktig handel for primærinnsidere
Mergers, Acquiqitions, Transferts
New
New establishment
News contracts
Other financial transaction
Other subject
Polls / Surveys
Products and services
Prospekt / opptaksdokument
Rapportering om betaling til myndigheter (land-for-land rapportering)
Rating
Renteregulering
Sales
Share history
Share introduction and issues
Takeover bids
Trends / Analyses
Utsteders meldeplikt ved handel i egne aksjer
Valg av hjemstat
Årsrapporter og revisjonsberetninger
Leverandør
Toggle Visibility
ActusNewsWire
BusinessWire
EQS Group
Euronext
GlobeNewswire
Les Echos
Marketwire
Modular Finance
Oslo Børs Newspoint
PR Newswire
Viser 51 - 100 av 123 resultater
Tid
Selskap
Tittel
Sektor
Kategori
29 Oct 2021
08:00 CEST
BIOPHYTIS
Biophytis Publie les Résultats Financiers Corrigés pour les Périodes Antérieures et au 30 Juin 2021
20103010 Biotechnology
Legal
07 Oct 2021
07:10 CEST
BIOPHYTIS
Biophytis to Restate Previously Issued Financial Statements
20103010 Biotechnology
Legal
07 Oct 2021
07:10 CEST
BIOPHYTIS
Biophytis va retraiter les états financiers publiés antérieurement
20103010 Biotechnology
Legal
06 Oct 2021
08:00 CEST
BIOPHYTIS
Biophytis organise un évènement avec les KOLs sur Sarconeos (BIO101) dans le traitement de la COVID-19 et de la Sarcopénie
20103010 Biotechnology
Legal
06 Oct 2021
08:00 CEST
BIOPHYTIS
Biophytis to host virtual KOL event on Sarconeos (BIO101) on its lead projects in COVID-19 and Sarcopenia
20103010 Biotechnology
Legal
04 Oct 2021
23:00 CEST
BIOPHYTIS
Biophytis announces the drawing of 2 new tranches of ORNANE under the 2020 Atlas Contract for €6 million
20103010 Biotechnology
Legal
04 Oct 2021
23:00 CEST
BIOPHYTIS
Biophyis annonce le tirage de deux nouvelles tranches d\'ORNANE dans le cadre du contrat Atlas 2020 pour 6 millions d’euros
20103010 Biotechnology
Legal
04 Oct 2021
08:00 CEST
BIOPHYTIS
Biophytis announces promising full results from the SARA-INT Phase 2b trial of Sarconeos (BIO101) in Sarcopenia at the 11th annual International Conference on Frailty and Sarcopenia Research (ICFSR) September 29 – October 2, 2021
20103010 Biotechnology
Legal
04 Oct 2021
08:00 CEST
BIOPHYTIS
Biophytis annonce des résultats complets prometteurs de l’étude de Phase 2-b, SARA-INT, évaluant Sarconeos (BIO101) dans la sarcopénie, au 11e Congrès International annuel sur la Fragilité et la Sarcopénie (ICFSR, 29 Septembre – 02 Octobre 2021
20103010 Biotechnology
Legal
29 Sep 2021
08:00 CEST
BIOPHYTIS
Biophytis to Present Full Results from the SARA-INT Phase 2b Trial of Sarconeos (BIO101) in Sarcopenia at the 11th annual International Conference on Frailty and Sarcopenia Research (ICFSR) September 29 – October 2, 2021
20103010 Biotechnology
Legal
29 Sep 2021
08:00 CEST
BIOPHYTIS
Biophytis présentera les résultats complets de L’étude de phase 2-b, SARA-INT, évaluant Sarconeos (BIO101) dans la sarcopénie, au 11e Congrès International annuel sur la Fragilité et la Sarcopénie (ICFSR, 29 Septembre – 02 Octobre 2021)
20103010 Biotechnology
Legal
17 Sep 2021
08:00 CEST
BIOPHYTIS
Biophytis reports H1 2021 financial results and provides business update
20103010 Biotechnology
Legal
17 Sep 2021
08:00 CEST
BIOPHYTIS
Biophytis publie ses résultats financiers du 1er semestre 2021 et fait le point sur ses activités
20103010 Biotechnology
Legal
15 Sep 2021
08:00 CEST
BIOPHYTIS
Biophytis announces DMC second interim analysis efficacy results in the promising zone allowing continuation of phase 2/3 COVA study with Sarconeos (BIO101) in COVID-19
20103010 Biotechnology
Legal
15 Sep 2021
08:00 CEST
BIOPHYTIS
Biophytis annonce les résultats de la deuxième analyse intermédiaire du DMC dans la « promising zone1 », permettant la poursuite de l’étude COVA de phase 2-3 de Sarconeos (BIO101) dans la COVID-19
20103010 Biotechnology
Legal
14 Sep 2021
08:00 CEST
BIOPHYTIS
Biophytis participera à plusieurs événements investisseurs et conférences clés du secteur
20103010 Biotechnology
Legal
14 Sep 2021
08:00 CEST
BIOPHYTIS
Biophytis to attend key upcoming investor events and industry conferences
20103010 Biotechnology
Legal
09 Sep 2021
08:00 CEST
BIOPHYTIS
Biophytis renforce son équipe de direction avec la nomination d’un nouveau Directeur Médical
20103010 Biotechnology
Legal
09 Sep 2021
08:00 CEST
BIOPHYTIS
Biophytis leadership is reinforced with new Chief Medical Officer appointment
20103010 Biotechnology
Legal
16 Aug 2021
08:00 CEST
BIOPHYTIS
Biophytis reçoit une recommandation favorable du DMC pour poursuivre le recrutement des patients dans l’étude COVA dans la COVID-19 basée sur l’analyse de l’innocuité de Sarconeos (BIO101)
20103010 Biotechnology
Legal
16 Aug 2021
08:00 CEST
BIOPHYTIS
Biophytis Receives Favorable Recommendation From Data Monitoring Committee (DMC) Based on Safety Analysis of Sarconeos (BIO101) to Continue Patient Recruitment in the COVA Study in COVID-19
20103010 Biotechnology
Legal
13 Aug 2021
23:00 CEST
BIOPHYTIS
Biophytis annonce l’émission de 4.950.000 actions nouvelles dans le cadre d’une augmentation de capital réservée à NEGMA et l’exécution des jugements du 16 mars et 16 juillet 2021
20103010 Biotechnology
Legal
13 Aug 2021
23:00 CEST
BIOPHYTIS
Biophytis Announces the Issue of 4,950,000 New Shares in a Capital Increase Reserved for NEGMA and the Performance of the Judgments of March 16, 2021 and July 16, 2021
20103010 Biotechnology
Legal
02 Aug 2021
08:00 CEST
BIOPHYTIS
BIOPHYTIS ANNOUNCES TOP LINE RESULTS OF SARA-INT PHASE 2 STUDY WITH SARCONEOS (BIO101) IN SARCOPENIA
20103010 Biotechnology
Legal
02 Aug 2021
08:00 CEST
BIOPHYTIS
BIOPHYTIS ANNONCE LES PREMIERS RÉSULTATS DE L\'ÉTUDE DE PHASE 2 SARA-INT AVEC SARCONEOS (BIO101) DANS LA SARCOPÉNIE
20103010 Biotechnology
Legal
19 Jul 2021
23:00 CEST
BIOPHYTIS
Judgment rendered on July 16, 2021 in the proceedings between Biophytis and Negma Group Ltd by the Execution Judge from the Paris Court of Justice
20103010 Biotechnology
Legal
19 Jul 2021
23:00 CEST
BIOPHYTIS
Jugement du Juge de l\'exécution du Tribunal judiciaire de Paris du 16 juillet 2021 dans l’affaire opposant Biophytis à Negma Group Ltd
20103010 Biotechnology
Legal
12 Jul 2021
08:00 CEST
BIOPHYTIS
Biophytis Presents Positive Preclinical Data on Sarconeos (BIO101) in COVID-19 at ECCMID 2021
20103010 Biotechnology
Legal
12 Jul 2021
08:00 CEST
BIOPHYTIS
Biophytis présente des données précliniques positives sur Sarconeos (BIO101) pour la COVID-19 à l\'ECCMID 2021
20103010 Biotechnology
Legal
08 Jul 2021
08:00 CEST
BIOPHYTIS
Biophytis Reinforces Leadership Teams with Three Senior Appointments
20103010 Biotechnology
Legal
08 Jul 2021
08:00 CEST
BIOPHYTIS
Biophytis Renforce ses Equipes de Direction avec Trois Nouvelles Nominations
20103010 Biotechnology
Legal
30 Jun 2021
23:00 CEST
BIOPHYTIS
Biophytis Sécurise la Fabrication de Sarconeos (BIO101) dans le Traitement de la COVID-19 avec une CDMO Internationale & Annonce les Prochains Jalons pour l’étude COVA de phase 2-3
20103010 Biotechnology
Legal
30 Jun 2021
23:00 CEST
BIOPHYTIS
Les Résultats de SARA-INT, Essai Clinique de Biophytis en Phase 2 évaluant l’Efficacité de Sarconeos (BIO101) dans le Traitement de la Sarcopénie seront Communiqués d’ici Août 2021
20103010 Biotechnology
Legal
30 Jun 2021
23:00 CEST
BIOPHYTIS
Biophytis Secures the Manufacturing of Sarconeos (BIO101) for COVID-19 with a Global CDMO & Announces the Next Milestones for the COVA Phase 2-3 Study
20103010 Biotechnology
Legal
30 Jun 2021
23:00 CEST
BIOPHYTIS
Results of Biophytis SARA-INT Phase 2 Trial with Sarconeos (BIO101) in Sarcopenia will be Released by August 2021
20103010 Biotechnology
Legal
18 Jun 2021
23:00 CEST
BIOPHYTIS
Biophytis annonce un nouveau financement en obligations convertibles pouvant atteindre 32 millions d’euros auprès d’Atlas, ainsi que le tirage de 2 tranches du Contrat Atlas 2020 pour 6 millions d’euros
20103010 Biotechnology
Legal
18 Jun 2021
23:00 CEST
BIOPHYTIS
Biophytis announces new convertible bond financing for up to €32 million with Atlas and drawing of 2 tranches under the 2020 Atlas Contract for €6 million
20103010 Biotechnology
Legal
12 May 2021
08:00 CEST
BIOPHYTIS
Biophytis Completed Recruitment of 155 Participants to the COVA Phase 2-3 Study with Sarconeos (BIO101) in COVID-19 allowing the 2nd Interim Analysis
20103010 Biotechnology
Legal
12 May 2021
08:00 CEST
BIOPHYTIS
Biophytis a terminé le Recrutement des 155 Patients de l’étude COVA de phase 2-3 avec Sarconeos (BIO101) dans le traitement de la COVID-19 permettant la réalisation de la Deuxième Analyse Intermédiaire
20103010 Biotechnology
Legal
11 May 2021
08:00 CEST
BIOPHYTIS
Results of the Combined General Meeting on May 10, 2021 All ordinary and extraordinary resolutions have been adopted
20103010 Biotechnology
Legal
11 May 2021
08:00 CEST
BIOPHYTIS
Résultats de l’Assemblée Générale Mixte du 10 mai 2021 Adoption de l’ensemble des résolutions à titre ordinaire et extraordinaire
20103010 Biotechnology
Legal
30 Apr 2021
08:00 CEST
BIOPHYTIS
L’Assemblée générale mixte de Biophytis aura lieu sur seconde convocation le 10 mai 2021 à Huis Clos
20103010 Biotechnology
Legal
30 Apr 2021
08:00 CEST
BIOPHYTIS
Biophytis – Second Combined General Meeting to Take Place on May 10, 2021 without the physical presence of its shareholders
20103010 Biotechnology
Legal
29 Apr 2021
08:00 CEST
BIOPHYTIS
Biophytis Receives €980,000 DeepTech Funding from BPI France for the development of Macuneos (BIO201) in dry AMD
20103010 Biotechnology
Legal
29 Apr 2021
08:00 CEST
BIOPHYTIS
Biophytis reçoit un financement de 980 000 € du plan Deeptech de Bpifrance pour le développement de Macuneos (BIO201) dans la DMLA
20103010 Biotechnology
Legal
27 Apr 2021
08:00 CEST
BIOPHYTIS
Biophytis - Convening of Another Combined General Meeting at a Later Date
20103010 Biotechnology
Legal
27 Apr 2021
08:00 CEST
BIOPHYTIS
Biophytis - Convocation à une seconde Assemblée générale mixte à une date ultérieure
20103010 Biotechnology
Legal
26 Apr 2021
08:00 CEST
BIOPHYTIS
Biophytis fait le Point sur ses Perspectives Opérationnelles concernant Sarconeos (BIO101) en amont de l’Assemblée Générale du 26 avril 2021
20103010 Biotechnology
Legal
26 Apr 2021
08:00 CEST
BIOPHYTIS
Biophytis Gives Operational Perspectives on its Sarconeos (BIO101) Ahead of its Upcoming AGM on April 26, 2021
20103010 Biotechnology
Legal
07 Jul 2017
20:24 CEST
BIOPHYTIS
Biophytis annonce l’émission d’une tranche d’ORNANEBSA d’un montant de 3,0 M€
Biotechnology
Corporate life
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Sider
«
« First
‹
‹‹
1
2
3
›
››
»
Last »
Company press releases subscription
×
To subscribe to Press releases from this issuer, visit the Subscription to Company news section in
Hjem
Markeder
Amsterdam
Cash Products
Aksjer
AEX index Stocks
AEX ESG Stocks
Indekser
Fond
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksopsjoner
Indeksfutures
Aksjeopsjoner
Utbyttederivater
Aksjefutures
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Brussel
Cash products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
Expert Market
BEL 20 Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Expert Market
Dublin
Stocks
Euronext regulated
Euronext Growth
ISEQ 20 Stocks
Indices
Funds
Bonds
Irish Government Bonds
DOL
Lisboa
Cash Products
Aksjer
Euronext regulated
Euronext Access
PSI Stocks
Indekser
Obligasjoner
Derivater
Indeksfutures
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Milan
Cash Products
Stocks
Euronext Milan
Euronext Growth Milan
Euronext Star Milan
Euronext Global Equity Market
EuroTLX
Trading After Hours
MIB ESG Stocks
Bonds
MOT
Euronext Access Milan
EuroTLX
Structured Products
SeDeX
EuroTLX
ETFs
Funds
Derivative products
All derivatives
Index futures
Index options
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
IPOs
Oslo
Aksjer, renter, indekser
Aksjer
Oslo Børs
Euronext Growth
Euronext Expand
Top performers
OBX aksjer
OBX ESG aksjer
OSEBX aksjer
OSEFX Aksjer
Seafood Aksjer
Shipping Aksjer
Aksjeindekser
Obligasjoner
Oslo Børs
Nordic Alternative Bond Market
Obligasjonsindekser
ETFer
Fond
Derivater
Derivative products
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Finanskalender
Primærinnsidere
Paris
Cash Products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
CAC 40 Stocks
CAC 40 ESG Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Aksjer
All Markets directories
All Markets
Euronext regulated
Euronext Growth
Euronext Access
Euronext Expand
Euronext Global Equity Market
EuroTLX
Trading After Hours
Selskapsmeldinger
Latest
Archive
Nye aksjenoteringer
Alle aksjenoteringer
Euronext Growth advisors
Euronext Tech Leaders
Family business
Indekser
Directory
Grønne indekser
Indices documents
Indices news
Indekser høringer
Kontakter Euronext-indekser
ETF-er
Directory
Grønne ETF-er
Fond
Directory
ESG Funds
Oslo Mutual Funds
Obligasjoner
Grønne obligasjoner
1.5° Bonds
All Markets directories
All Markets
Amsterdam
Brussels
Dublin
Lisbon
Oslo
Milan
Paris
Strukturerte produkter
Directory / search
Bid-Only trading status
Trading Turbos in the Netherlands
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
ETF opsjoner
Kontraktsspesifikasjoner
Tick sizes
Rapportering av handler
Leverandørkoder markedsdata
Råvarer
Quotes
Quotes snapshot
Milling Wheat futures
Rapeseed futures
Corn futures
European Durum Wheat Futures
Milling Wheat options
Rapeseed options
Corn options
Bortfallskalendre
Bortfall
Wholesale Trading
Commitments of Traders (CoT) report
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Knowledge Centre
Bid & Ask
Options Investing E-learning
Contract Specifications
Position Management
Intrinsic Value
Premium & Valuation
Moneyness
Positions
Euronext News
Ressurser
Statistikk & rapporter
Quality of execution
Åpningstider
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Key Information Document
Class level
Product group level
Notices / Corporate actions
Cash Notices / Corporate actions
Derivatives corporate actions
All Corporate Actions
Latest
Unusual Contract Sizes, Dividends
Corporate Action Services
Corporate Action Policies
Derivatives notices
Markedshendelser
Suspenderte instrumenter
Stressed Market Conditions
Brudd på Double Cap limits
Ekstraordinære markedsforhold
Diverse meldinger
Market status
Medlemsliste
Issuers compliance
Hvor du finner hva